Navigation Links
Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty
Date:6/14/2013

ments include (but are not limited to) statements about expected benefits and risks associated with the Further Increased Offer; projections or expectations of profit attributable to shareholders; anticipated provisions or write-downs, economic profit, dividends, capital structure or any other financial items or ratios; statements of plans, objectives or goals of Elan, the Elan Group, RP Management or Royalty Pharma following the Further Increased Offer; statements about the future trends in interest rates, liquidity, foreign exchange rates, stock market levels and demographic trends and any impact that those matters may have on Elan, the Elan Group, RP Management or Royalty Pharma following the Further Increased Offer; statements concerning any future Irish, US or other economic environment or performance; statements about strategic goals, competition, regulation, regulatory approvals, dispositions and consolidation or technological or regulatory developments; and statements of assumptions underlying such statements.

Forward looking statements only speak as of the date on which they are made, and the events discussed in this announcement may not occur. Subject to compliance with applicable law and regulation, Royalty Pharma is not under any obligation to update publicly or revise forward looking statements, whether as a result of new information, future events or otherwise.

Rule 8 - Dealing Disclosure Requirements

Under the provisions of Rule 8.3 of the Irish Takeover Rules, if any person is, or becomes, "interested" (directly or indirectly) in 1% or more of any class of "relevant securities" of Elan, all "dealings" in any "relevant securities" of Elan (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by not later than 3.30 pm (Irish time) on the "business day" following the date of the relevant transaction. This requirement will continue until the date on w
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Royalty Pharma Increases Offer to Acquire Elan to $13.00 Per Share in Cash Plus a Contingent Value Right of Up to $2.50 Per Share
2. Royalty Pharma Statement Regarding Elan Law Suits
3. Cadwalader Advises Elan Corporation in Billion Dollar Royalty Deal
4. Royalty Pharma Statement Regarding Elan Proposal
5. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
6. Cowen Healthcare Royalty Partners Raises $1 Billion
7. Smart Consulting Group and The Catalyst Group Form Alliance to Supply Quality Compliance Consulting Services For the Pharmaceutical Industry
8. Pursuit's Elissa Guerra and Eunjoo Pluenneke to Present on Mobile Strategy at Digital Pharma West Conference
9. MEI Pharma Adds Former YM BioSciences CEO Nick Glover To Board Of Directors
10. Frost & Sullivan Recognizes Sciformixs Continued Growth in the Increasingly Complex Pharmaceutical KPO Market
11. Auxilium Pharmaceuticals, Inc. To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... /PRNewswire/ - Inimex Pharmaceuticals, Inc. announced today that it has ... , Abrams brings more than 25 years of drug discovery ... the nuclear medicine imaging agent, Cardiolite, and worked from 1984 ... Biomedical Research Worldwide. In 1996, Abrams led the establishment of ...
... , , , , , ... , AUDIO: A team of scientists from Washington ... Click here for more information. , , ... , , , , , ...
... , , ROCKVILLE, Md., Nov. 20 ... it has priced an underwritten public offering of 6,800,000 shares ... of $3.30 per share. The approximately $21 million of ... be used for preclinical studies and clinical trials of our ...
Cached Biology Technology:Inimex Announces Appointment of New CEO 2Amaizing: Corn genome decoded 2Amaizing: Corn genome decoded 3Amaizing: Corn genome decoded 4Novavax Prices Public Offering of Common Stock 2
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced ... India 2015-2019" report to their offering. ... market is the adoption of multimodal biometric systems. ... of an individual for verification and identification purposes. ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... release is available in French . ... Vice-Chancellor of Concordia University, is pleased to announce the ... solar simulator. The Environmental Chamber will be built through ... Governments, through the Knowledge Infrastructure Program. The Environmental ...
... , This release is available in ... Vice-Chancellor of Concordia University is pleased to announce the ... Structural and Functional Genomics (CSFG). The Centre will ... the Federal and Provincial Governments through the Knowledge Infrastructure ...
... activity levels fall and rise to the beat of our ... sleeping and feeding patterns to the energy available to our ... by light, the pacemakers in peripheral organs are set by ... Now, researchers at the Salk Institute for Biological Studies shed ...
Cached Biology News:Concordia University to build innovative Environmental Chamber 2Concordia University to construct new building for genomics research 2The food-energy cellular connection revealed 2The food-energy cellular connection revealed 3
Rabbit polyclonal to Peptide E ( Abpromise for all tested applications)....
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
...
...
Biology Products: